Research and Markets: Kazakhstan Pharmaceuticals and Healthcare Report Q2 2012

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/f2aa494f/kazakhstan_pharmac) has announced the addition of the "Kazakhstan Pharmaceuticals and Healthcare Report Q2 2012" report to their offering.

Business Monitor International's Kazakhstan Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Kazakhstan's pharmaceuticals and healthcare industry.

BMI View

Kazakhstan remains the most accessible and competitive pharmaceutical market in Central Asia and the growing expectation it will gain World Trade Organisation (WTO) membership by the end of 2012 is driving continued regulatory reform. The acquisition of market leader Chimpharm and the reported imminent sale of a large stake in top-three player Global Pharm to a Turkish buyer reflect the strength of the market. Clearly, the provision of loans by the Kazakhstan Development Bank and Innovation Fund for expansion under the country's Accelerated Industrial Development Plan, as well as forward contracts signed with state wholesaler guaranteeing a market for their products, has greatly enhanced the value of local companies. There are, however, major questions with regard to how Russia and Kazakhstan will reconcile their Customs Union with Belarus with WTO membership and - following snap parliamentary polls - the longevity of the current regime and broader social stability.

Key Trends And Developments

- The Caspian Group, a shareholder in leading local manufacturer Global Pharm, reported that it is merging' with Turkish pharmaceutical company Abdi Ibrahim. This follows reports in late 2011 that the company was up for sale. If true, the deal would follow fast on the heels of the sale of Chimpharm to Polpharma.

- A less cheery assessment of state-backed wholesale company, SK Farmatsiya, has come from the Accounts Committee for Control over Execution of the Public Budget, the state spending watchdog. A press release published in January 2012 summarised the committee's concerns that the wholesaler had yet to develop the required logistical capacity to fulfil its broader agenda of creating efficient infrastructure for pharmaceuticals for the state hospital sector.

Key Topics Covered

- Executive Summary

- SWOT Analysis

- Pharmaceutical Risk Reward Ratings

- Kazakhstan - Market Summary

- Industry Forecast Scenario

- Competitive Landscape

- Company Monitor

- Country Snapshot: Kazakhstan Demographic Data

- Glossary

- BMI Methodology

Companies Mentioned

- Chimpharm

- Romat ,vartis (Lek and Sandoz)

- Sanofi

- GlaxoSmithKline

- Nycomed

- Merck & Co

- Pfizer

- Ranbaxy

For more information visit http://www.researchandmarkets.com/research/f2aa494f/kazakhstan_pharmac